These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 7650492)

  • 1. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.
    Arnold D; Faath S; Rammensee H; Schild H
    J Exp Med; 1995 Sep; 182(3):885-9. PubMed ID: 7650492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation.
    Lammert E; Arnold D; Rammensee HG; Schild H
    Eur J Immunol; 1996 Apr; 26(4):875-9. PubMed ID: 8625982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96.
    Arnold D; Wahl C; Faath S; Rammensee HG; Schild H
    J Exp Med; 1997 Aug; 186(3):461-6. PubMed ID: 9236199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phylogenetic conservation of gp96-mediated antigen-specific cellular immunity: new evidence from adoptive cell transfer in xenopus.
    Maniero GD; Robert J
    Transplantation; 2004 Nov; 78(10):1415-21. PubMed ID: 15599304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis.
    Singh-Jasuja H; Toes RE; Spee P; Münz C; Hilf N; Schoenberger SP; Ricciardi-Castagnoli P; Neefjes J; Rammensee HG; Arnold-Schild D; Schild H
    J Exp Med; 2000 Jun; 191(11):1965-74. PubMed ID: 10839811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of cytotoxic T cells in vitro by recombinant gp96 fusion proteins irrespective of the 'fused' antigenic peptide sequence.
    Moré S; Breloer M; Fleischer B; von Bonin A
    Immunol Lett; 1999 Aug; 69(2):275-82. PubMed ID: 10482363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96.
    Ishii T; Udono H; Yamano T; Ohta H; Uenaka A; Ono T; Hizuta A; Tanaka N; Srivastava PK; Nakayama E
    J Immunol; 1999 Feb; 162(3):1303-9. PubMed ID: 9973383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On cross-priming of MHC class I-specific CTL: rule or exception?
    Zinkernagel RM
    Eur J Immunol; 2002 Sep; 32(9):2385-92. PubMed ID: 12207322
    [No Abstract]   [Full Text] [Related]  

  • 9. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins.
    Binder RJ; Kelly JB; Vatner RE; Srivastava PK
    J Immunol; 2007 Dec; 179(11):7254-61. PubMed ID: 18025167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein-peptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1.
    Navaratnam M; Deshpande MS; Hariharan MJ; Zatechka DS; Srikumaran S
    Vaccine; 2001 Jan; 19(11-12):1425-34. PubMed ID: 11163665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
    Tremblay N; Fontaine P; Perreault C
    Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
    J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.
    Udono H; Levey DL; Srivastava PK
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3077-81. PubMed ID: 7909157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
    Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
    Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of peptides with heat shock protein gp96 occurs in vivo and not after cell lysis.
    Ménoret A; Peng P; Srivastava PK
    Biochem Biophys Res Commun; 1999 Sep; 262(3):813-8. PubMed ID: 10471407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minor histocompatibility antigen-specific MHC-restricted CD8 T cell responses elicited by heat shock proteins.
    Robert J; Gantress J; Rau L; Bell A; Cohen N
    J Immunol; 2002 Feb; 168(4):1697-703. PubMed ID: 11823499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation.
    Lu WW; Zhang H; Li YM; Ji F
    World J Gastroenterol; 2017 Jun; 23(24):4390-4398. PubMed ID: 28706421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodominant minor histocompatibility antigen peptides presented by H2Db molecules.
    Nevala WK; Wettstein PJ
    Transplantation; 1997 Nov; 64(9):1323-30. PubMed ID: 9371675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.